Clinical Trial Update: TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the combination of the TLR8 agonist VTX-2337 with cetuximab for locally advanced, recurrent, or metastatic squamous cell carcinoma of t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Salivary Gland Cancer
• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• ERBITUX (cetuximab)
• VTX-2337 (TLR8 agonist)

Snippet

Sponsor: University of Washington | Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 1 | Status: COMPLETED